Patents Assigned to Antagonis Biotherapeutics GmbH
  • Glycosaminoglycan-antagonising fusion proteins
    Patent number: 10703790
    Abstract: The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: July 7, 2020
    Assignee: ANTAGONIS BIOTHERAPEUTICS GMBH
    Inventor: Andreas Kungl
  • Glycosaminoglycan-antagonising fusion proteins and methods of using same
    Patent number: 10047133
    Abstract: The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 14, 2018
    Assignee: Antagonis Biotherapeutics GmbH
    Inventor: Andreas Kungl